Back to all Programs

Register here

Related Materials

Past event

International Workshop on HIV & Hepatitis Co-infection 2017

Viral Hepatitis and Liver Disease

Management of HCV in intravenous drug users: special considerations | Rui Sarmento e Castro, MD, PhD

Viral Hepatitis and Liver Disease

Hepatitis E in HIV | Kenneth Sherman, MD, PhD

Viral Hepatitis and Liver Disease

News on hepatitis delta and HIV infections | Vincent Soriano, MD, PhD

Viral Hepatitis and Liver Disease

Management of end-stage liver disease in HIV patients | Ana Morbey, MD

Viral Hepatitis and Liver Disease

EASL highlights 2017 | Jürgen Rockstroh, MD

Viral Hepatitis and Liver Disease

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

Viral Hepatitis and Liver Disease

Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

Viral Hepatitis and Liver Disease

Virologist's perspective | Charles Boucher, MD, PhD

Viral Hepatitis and Liver Disease

Pharmacologist's perspective | David Back, PhD

Viral Hepatitis and Liver Disease

Are there any special populations in treatment of HCV left? | Douglas Dieterich, MD

Viral Hepatitis and Liver Disease

The use of HIV+ or HCV+ organs in transplantation | Stefano Fagiuoli, MD

Viral Hepatitis and Liver Disease

Non liver and survival benefits of SVR in HCV | Marion Peters, MD

Viral Hepatitis and Liver Disease

NASH and NAFLD in HIV: same or different? | Mariana Machado, MD

Viral Hepatitis and Liver Disease

Antifibrotics and fatty liver drugs in the pipeline | Sanjay Bhagani, MD

Viral Hepatitis and Liver Disease

HCV elimination program in Georgia: Successes and challenges | Nikoloz Chkhartishvili, MD, MS, PhD

Viral Hepatitis and Liver Disease

What challenges remain in viral hepatitis | Jürgen Rockstroh, MD